[SaneVax: What would happen if scientists discovered that naturally acquired HPV infections helped reduce the risk of future infections and abnormal cell development? Would vaccine manufacturers admit they may have made a mistake and go back to the drawing board? Would the FDA be a little more cautious next time they considered fast-tracking a vaccine for which no health crisis exists? Would medical professionals begin to understand that not all vaccines are SANE?]
HPV Vaccine Maker’s Study Proves Natural HPV Infection Beneficial, Not Deadly
By Sayer Ji, Founder of GreenMedInfo
Behind every vaccine is an assumption. That HPV causes cervical cancer, that cervical cancer causes death, and that a vaccine can effectively interfere with this linear relationship is the assumption to be examined in this article. Cervarix is a vaccine recommended to girls beginning as early as 9 years old, intended to protect against HPV strains 16 and 18 upon completion of a 3 dose series. It is an aluminum-containing product, with notable “immunogenicity”.
A new GlaxoSmithKline (GSK) funded study published in the Journal of Infectious Diseases has revealed that HPV infection, resulting in naturally acquired human papilloma virus (HPV) antibodies, reduces the risk for new infection and cervical abnormalities linked to cancer in non-HPV vaccinated subjects.
In addition to this startling finding – additional GSK-funded research from this year revealed that the HPV vaccine may not protect women against high-grade squamous intraepithelial lesions, dysplasias.
If, in fact, the HPV vaccines do not work as widely advertised, and natural HPV infectious exposures actually protect against the progression of HPV linked cervical changes to cancer, then taken together, both these findings challenge the most fundamental assumptions within vaccine science (aka vaccinology), and render highly dubious the oft repeated rhetoric that natural HPV infection is juggernaut –like deadly force the best defense against which are universal immunization campaigns.
HPV Infection Protects Against New Infection and Cervical ‘Premalignancies’
The groundbreaking new study titled, Risk of newly detected infections and cervical abnormalities in women seropositive for naturally-acquired HPV-16/18 antibodies: analysis of the control arm of PATRICIA, analyzed data from the non-vaccinated control arm of the Papilloma Trial against Cancer in Young Adults (PATRICIA), to ascertain whether natural HPV16 and HPV18 antibodies reduced the risk for new HPV infection and/or cervical abnormalities over a 300 day period. A total of 16,656 women were included in the study’s control arm (8,193 women in the HPV16 analysis and 8,463 women in the HPV18 analysis), with none of the women being administered the HPV vaccine.
It should be noted that this is one of the first studies to look at the natural history of HPV infection and immunity, as well as one of the first studies to show the validity of using the control arm data from vaccine efficacy trials. The control arm did, however, receive three doses of the Hepatitis A vaccine. As there are no vaccine studies in existence using a true non-vaccinated control group, the natural incidence of a disease, as well as the true risks of a vaccine cannot be effectively assessed.
The study found that the presence of natural antibodies against HPV16, considered one of the most malignant of the over 120 unique types identified, lowered the risk for newly detected infection and a type of abnormal pap smear result known as ASC-US+ or ‘atypical squamous cells of undetermined significance’. The same protective effect was found for natural HPV18 antibodies, only to a lesser extent.
While the presence of HPV antibodies (seropositivity) overall was not associated with the development of the so-called cervical ‘premalignancy’ known as CIN1+, i.e. cervical intraepithelial neoplasia grade 1 or higher, those with the highest antibody levels at baseline had a significantly reduced risk of developing CIN1+ compared to women without detectable HPV antibodies (seronegative women).
Given that the entire justification for vaccination is based on the observation that surviving natural exposures to infectious challenges results in lasting immunity, this finding is not that surprising. HPV is no doubt one of countless infectious challenges the body’s elaborate and highly effective adaptive immune system countermands, often subclincally/asymptomatically . Even the authors of the study acknowledged: “Naturally acquired antibodies can remain detectable for at least 4 to 5 years, albeit at much lower levels than those induced by vaccination.” Given the outcomes demonstrating protective efficacy of these lower levels of antibodies, questions may be raised about other elements of the immune system at play in successful pathogenic defense.
Read the entire article here.